swg_trd, I think one must make a difference between cancer treatment, which can ONLY be applied to people that have a cancer and diagnostics that are applied to all people testing for cancer and for which MANY (25-50% depending on what area of the world we talking off) are NOT diagnosed with cancer.
The test that PPHM has will not ONLY be applied to people with cancer. It will, IMO, MULTIPLE times be applied to people WITHOUT CANCER (rendering the application field MUCH bigger). For those people that ARE diagnosed with cancer there ALSO will not just be a SINGLE test but they will undergo MULTIPLE tests as part of the follow-up cycle of the treatment they get (unrelated to WHAT treatment they get).
That is what I meant that there is no way one writes a Market Value report (in the past) that didn't include the knowledge of such ALL ROUND TEST as PPHM has and that would be correct. I can accept for myself that the diagnostics market is MUCH bigger then the treatment market but that in some way the better detection due to tests as PPHM provides will in turn increase the demand for treatment.
But OK, I have been out and I am currently under attack by two accomplices that are trying to pull me away from my computer. So I'll leave it to the above and will read tomorrow if I made sense.
Have a nice week-end all.
Market Data 
Markets 
